APA (7th ed.) Citation
(2026). Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program. Biologics: Targets & Therapy.
Chicago Style (17th ed.) Citation
"Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program." Biologics: Targets & Therapy 2026.
MLA (9th ed.) Citation
"Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program." Biologics: Targets & Therapy, 2026.
Warning: These citations may not always be 100% accurate.